Antihistamines in severe/chronic rhinitis

Clinical and Experimental Allergy, Supplement

Volumn 28, Issue 6, 1998, Pages 49-53

  Bousquet, J ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Allergic rhinitis; Cardiac safety; Ebastine; Efficacy; H1 antagonists; Safety tolerability; Symptoms

Indexed keywords

ASTEMIZOLE; CHROMONE DERIVATIVE; CORTICOSTEROID; EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ANTICHOLINERGIC EFFECT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QT INTERVAL; RHINITIS; SEDATION;

BUTYROPHENONES; HISTAMINE H1 ANTAGONISTS; HUMANS; PIPERIDINES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SLEEP STAGES; TORSADES DE POINTES;

EID: 0032409874     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. International Rhinitis Management Group. International consensus report on the diagnosis and management of rhinitis. Allergy Supplement 1994; 19 (Suppl.):5-34.
2. van Cauwenberg P. Management - the specialists' opinion. Clin Exp Allergy 1998; 28 (Suppl. 6): 29-33.
3. Warren R, Simpson H, Hilchie J et al. Drugs detected in fatally injured drivers in the Province of Ontario. In: Eddberg L. (ed.) Alcohol, Drugs, and Traffic Safety. Stockholm: Almquist and Wiksell 1981.
4. Mattila MJ, Kuitunen T, Plétan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol 1992; 43:179-84.
5. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36:233-52.
6. Tobin JR, Doyle TP, Ackerman AD et al. Astemizole-induced cardiac conduction disturbances in a child. J Am Med Assoc 1991; 266:2737-10.
7. Broadhurst P, Nathan AW. Cardiac arrest in a young woman with the long QT syndrome and concomitant astemizole ingestion. Br Heart J 1993; 70:460-70.
8. Herings RM, Stricker BH, Leufkens HG et al. Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands. Pharm World Sci 1993; 15:212-8.
9. Goss JE, Ramo BW, Blake K. Torsades de pointes associated with astemizole (Hismanal) therapy [letter]. Arch Intern Med 1993; 153:2705.
10. Hasan RA, Zureikat GY, Nolan BM. Torsade de pointes associated with astemizole overdose treated with magnesium sulfate. Pediatr Emerg Care 1993; 9:23-5.
11. Sakemi H, VanNatta B. Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J 1993; 125:1436-8.
12. Saviuc P, Danel V, Dixmerias F. Prolonged QT interval and torsade de pointes following astemizole overdose. J Toxicol Clin Toxicol 1993; 31:121-5.
13. Snook J, Boothman-Burrell D, Watkins J et al. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988; 42:257-9.
14. Simons FE, Kesselman MS, Giddins NG et al. Astemizole-induced torsade de pointes [letter]. Lancet 1988; ii:624.
15. Craft TM. Torsade de pointes after astemizole overdose. Br Med J Clin Res Ed 1986; 292:660.
16. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 1997; 96:144-6.
17. Vorperian VR, Zhou Z, Mohammad S et al. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardio 1996; 28:1556-61.
18. Katyal VK, Choudhary D. Occurrence of torsade de pointes with use of astemizole. Indian Heart J 1994; 46:181-2.
19. Rao KA, Adlakha A, Verma-Ansil B et al. Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clin Proc 1994; 69:589-93.
20. Connell L, Alderfer V, Garcia J. Electro-cardiographic evaluation of ebastine in double-blind allergic rhinitis. Clin Allergy 1995; 50 (Suppl. 26):105.
21. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996; 52 (Suppl. 1):20-5.
22. Bousquet J. Ebastine 10 or 20 mg once-daily is effective for treatment of perennial allergic rhinitis: a 12-week double-blind, placebo-controlled study. Allergy 1997;52 (Suppl. 37): 205 [Abstract].
23. Davies RJ. Comparative efficacy and safety of once-daily ebastine 10 or 20 mg and loratadine 10 mg in the treatment of perennial allergic rhinitis. Allergy 1997; 52 (Suppl. 37): 168 [Abstract].